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18kg in 7/11). At baseline 6 patients were NYHA Class II and 5 were Class III. Clinical
procedural success was achieved in 9/11. One patient experienced a major ischemic stroke
(MRS3 at discharge; final 90-day adjudication pending). A second had a mean
post-procedure gradient of 22mmHg (above the 20mmHg VARC threshold) although the
valve was functioning well (post-procedure AVA 1.6cm2). Partial resheathing
was performed in 4/4 patients; none required full retrieval. Mean aortic gradient
was 53.920.9mmHg at baseline and 13.73.7mmHg at discharge. Mean
AVA was 0.70.2cm2 at baseline and 1.50.2cm2 at discharge. Paravalvular AR
was mild in 2 patients, trivial in 1, absent in 8. Conduction disturbance requiring
a new pacemaker occurred in 4 patients (2 with complete AV block). There were
no deaths or MIs through 7 days.
Conclusions: Early feasibility results suggest that the Lotus Valve can be positioned
precisely and successfully with virtually no AR and low clinical event rates through
discharge, supporting further study in a larger, more rigorous trial. Three-month data will
be presented for the first time at TCT 2012.
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Long-term Intravascular Blood-Pressure Monitoring with a Novel, Wireless
Sensor System – Results from Chronic In-vivo Studies
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Background: Long-term blood-pressure (BP) monitoring is a vital necessity for
physicians to prescribe appropriate medical treatment for malign hypertension patients in
order to reduce the incidence of secondary consequences such as stroke, kidney failure or
heart insufficiency. However, current devices are still not suited for long-term measure-
ment (several weeks to months). Moreover, they usually measure the peripheral blood
pressure which significantly differs to the central blood pressure known to be the better
indicator for vascular diseases. In order to address this need, we developed and conducted
in-vivo tests on a novel, fully-implantable, wireless blood-pressure monitoring system.
Methods: The monitoring system was tested for six months in 12 chronic ovine models.
The sensor was implanted with X-ray-control in the femoral artery by means of a
dedicated sheath (PASIS). Reference measurements were recorded with gold standard
pressure sensors after implantation. Position and proper functioning of the sensor were
controlled via regular readout measurements and CTs. At the end of each trial, a
histological examination was conducted.
Results: Chronic in-vivo studies revealed that blood pressure measurement over a period
of six months was possible with the novel implantable sensor system. Stable pressure
histories were recorded. However, the mechanical resilience of the sensor system requires
improvement. The in-vivo tests in the femoral artery of sheep produced high stress on the
sensors system. Several implanted systems became inoperative despite efforts to stiffen the
sensor-cable. The histological analysis detected no thrombi. Mild inflammatory reactions
were found at the vessel insertion site in several cases.
Conclusions: The results of the chronic in-vivo tests on the novel fully-implantable
blood-pressure monitoring system were encouraging. Improvements need to be made
regarding the mechanical resilience of the system and the coating. Additional trials at a
modified implantation spot will be conducted in order to reveal further insights regarding
system performance.
TCT-106
BioInnovate Ireland: A Multidisciplinary Approach To Medical Device
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Waqar Aziz1, Wayne Allen1, Colin Forde1, Marie Travers1, Mark Bruzzi1,
Faisal Sharif1
1National University of Ireland, Galway, Galway, Ireland
Background: A 10 month research program; to find and validate a relevant unmet
clinical need in cardiovascular care prior to developing solutions.
Methods: A multidisciplinary team of four members with experience in clinical
medicine, engineering, business and software design received four weeks’ training in
basic anatomy, physiology, market analysis, clinical needs finding and concept genera-
tion, intellectual property (I.P.), regulatory, reimbursement and business planning. The
fellows jointly agreed an acceptance criteria e.g. market size, measurable endpoints etc to
aid future decision making. For eight weeks the team were attached to tertiary care
hospitals to understand the patient cycle of care and the perspectives of all the
stakeholders impacting in/out-patient care and to observe a range of in-hospital proce-
dures. This resulted in nearly 2000 observations which were translated into 120 problem
statements. These problems were researched in terms of incidence, prevalence, disease
pathophysiology, existing treatments effectiveness, market size etc. This insight and
filtering against the acceptance criteria enabled further elimination. The remaining
problems were translated into clinical needs statements and validated by speaking to key
stakeholders, in-depth medical literature review and competitor analysis. As a result eight
needs statements emerged. The resultant concepts from brainstorming of the needs were
screened against agreed need specifications and pre-existing I.P. Further literature and
primary research, filtering and elimination led to a final need entitled: A cost effective, fast
way to embolize a blood vessel. This had emerged from observing that current
embolization devices are deficient e.g. need for multiple coils, migration, recanalization,
and high prices.
Results: Funding was successfully applied for and secured from Enterprise Ireland to
enable prototyping with proof of concept via bench testing and animal studies.
Conclusions: This multidisciplinary innovation research program brings together the key
stakeholders involved with medical devices and enables the development of a rich
network and expertise that will promote patient care through future medical device
development.
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Background: A significant proportion of patients with severe mitral regurgitation (MR),
have severe comorbidities and are not candidates for conventional surgery because of high
operative risk. The field of percutaneous mitral valve (MV) repair is developing and many
technologies are now under investigation. To date, trans-catheter valve implantation is
limited to pulmonary and aortic valve replacement. The aim of our study wad to
demonstrate the safety and feasibility of minimally invasive trans-catheter implantation of
a novel self-expanding MV specifically designed for the unique complex anatomical
configuration of the mitral apparatus - the TIARA self-expanding bioprosthetic valve.
Methods: Using a trans-apical approach, TIARA valves were successfully implanted in
29/36 (81%) domestic swine with fluoroscopic and 3D transesophageal echocardio-
graphic (TEE) guidance. Follow-up varied from 90 minutes to 96 hours. The valves were
delivered using a short flexible 30F delivery catheter.
Results: Total procedure time ranged from 17 to 26 minutes, and the prosthesis
deployment time ranged from 5 to 13 minutes. In the 29 successful implantations, TEE
demonstrated excellent function and alignment of the TIARA prosthesis, with no left
ventricular outflow tract obstruction, no pericardial effusion, no encroachment on the
aortic valve, and no trans-valvular gradients. Significant paravalvular leaks were only seen
in cases of either MV annulus-prosthesis mismatch or failed implantation. Macroscopic
evaluation of the explanted hearts demonstrated stable and secure positioning of the valves
in all planes of the mitral apparatus with no evidence of injury to the ventricular or atrial
walls.
Conclusions: We report our successful initial pre-clinical experience with the TIARA
trans-catheter self-expanding mitral bioprosthetic valve. We have demonstrated that the
implantation of the TIARA valve is a feasible, safe, and relatively straightforward
procedure, which results in a stable and well-functioning mitral valve bioprosthesis.
Successful completion of long-term pre-clinical trials of the TIARA is ongoing which will
lead the way to human clinical trials.
TCT-108
Performance and Safety of the TRUE Dilatation™ Balloon Valvuloplasty
Catheter for Aortic Balloon Valvuloplasty in Patients Undergoing TAVI
Felix Woitek1, Stephan Haussig1, Norman Mangner1, Robert Höllriegel1,
Enno Boudriot1, Marion Zimmer1, Beate Rott1, David Holzhey1, Friedrich Mohr1,
Gerhard Schuler1, Axel Linke1
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Background: Valvuloplasty (BAV) using the currently available balloons - to prepare
the valve annulus for the implant of a transcatheter heart valve - is associated with balloon
slippage and rupture in up to 17 % of the cases, which carries an increased risk of stroke.
The TRUE Dilatation™ Balloon Valvuloplasty Catheter, constructed of inner and outer
film layers that encompass a flexible matrix center embedded with high performance
fibers, was developed to allow a fast and precise dilatation of the aortic valve in the
absence of balloon rupture. It was aim of the present study to assess the performance of
MONDAY, OCTOBER 22, 8:00 AM–6:15 PMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/ORAL/Interventional Innovation B33
O
R
A
L
S
the TRUE Dilatation™ Balloon Valvuloplasty Catheter in patients undergoing transcath-
eter aortic valve implantation (TAVI).
Methods: Between January and May 2012, a total of 18 patients (pts) with high grade
aortic stenosis underwent valvuloplasty of the aortic valve using the TRUE Dilatation™
Balloon Valvuloplasty Catheter prior to TAVI. Several performance measures were
evaluated and graded from 1 to 10, which 10 indicating best performance.
Results: Subjects were 83 6 years old, logistic EuroSCORE 16 7%, STS 9.6 4.5.
The mean aortic gradient was 4819mmHg, the valve orifice area was 0.66 0.19 cm2.
BAV was successful in all cases. Neither balloon nor annular rupture occurred in any
case,. Balloon inflation and deflation times were less than 2 seconds, The grade for the
performance measure “ease of catheter insertion through introducer sheath” was 9.30.5
points, 9.10.5 for “ease of passing catheter over aortic arch, ease of catheter crossing
over aortic valve” 9.20.7 points, for “speed of balloon inflation” 9.60.6 points, for
“ability to dilate aortic valve without balloon slippage” 8.91.7 points, and for “speed of
balloon deflation” 8.91.1 points. Five pts (28%) received and Edwards SAPIEN XT and
12 pts (72%) a Medtronic CoreValve Prosthesis after BAV. The 30 day stroke and
mortality rates were zero and 5.6%.
Conclusions: This study shows that the TRUE Dilatation™ Balloon Valvuloplasty
Catheter has an excellent performance with fast inflation and deflation times in patients
with severe aortic stenosis in the absence of harmful side effects.
TCT-109
A New Generation Transcatheter Heart Valve with a Novel Nanocomposite
Material and Fully Retrievable Design
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Background: Transcatheter aortic valve implantation (TAVI) procedures offer remark-
able benefits for high risk patients with severe aortic stenosis. However, the current TAVI
devices are associated with complications such as lack of repositionability, paravalvular
leakage and atrio-ventricular block. Moreover, there is no long-term clinical data about the
durability of current tissue-derived TAVI prostheses and leaflet degradation during the
loading into the catheter remains a serious concern.
Methods: A new generation transcatheter aortic valve (TAV) has been developed by our
group at University College London. The UCL-TAV benefits from leaflets made of a
novel nanocomposite polymer encompassed by a self-expandable Nitinol stent. The
polymer is composed of a polycarbonate urea urethane soft segment (PCU) and hard
segment derived from polyhedral oligomeric silsesquioxane (POSS) nanoparticles
through covalent bonding forming pendant chain functional groups. POSS-PCU nano-
composite possesses enhanced physiochemical properties, resistance to calcification and
thrombosis with superior in-vivo biostability. It has been successfully implanted in human
in the form of a small calibre bypass graft, lacrimal duct conduit, and more recently as the
world’s first synthetic trachea. The UCL-TAV design allows for multi-stage expansion of
the prosthesis providing controlled deployment, and is fully retrievable in the case of
misplacement.
Results: POSS-PCU demonstrated superior mechanical properties compared to porcine
and bovine pericardial tissues. Initial prototypes of UCL-TAV were successfully pro-
duced using a consistent manufacturing technique, and tested for collapse and re-
expansion over several cycles with no observable structural damage. Owing to its thin
polymeric leaflets membrane, the valve can be crimped in to a catheter equal to or less
than 18 Fr to provide easier vascular access, and the design has improved anchoring and
sealing with no need for excessive radial force.
Conclusions: Having a fully retrievable design as well as an advanced material, the
UCL-TAV can overcome the main limitations of current TAVI devices. The UCL-TAV
is currently under pre-clinical evaluation.
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Background: Percutaneous tricuspid valve implantation has received little attention,
mainly due to the unstructured annulus and the associated difficult stentframe anchoring.
Tricuspid regurgitation is commonly a result of right ventricle-dilation secondary to left
heart diseases. A novel anatomically adapted tricuspid heart valve prosthesis, consisting
of a vena cava superior-stent (CSA) and a tricuspid annulus-stent (ASA) connected by
flexible struts, was developed. Anatomical CT-data of a porcine heart (65 kg, female) was
post-processed using Mimics and 3-matic (Materialise, Leuven, Belgium) and relevant
dimensions were considered in the stent design process. The anchoring of the prosthesis
relies primarily on the CSA-stent and is supported by the valved ASA-stent. First
experience with this anchoring concept, using a design with an additional vena cava
inferior-stent, was gained in animal trials which demonstrated the feasibility of the
concept.
Methods: Finite element simulations were performed with Abaqus (Simulia, Providence,
USA) to analyze the crimping process of the arched stent-construct and the loading on a
straight catheter. A custom trileaflet heart valve was sewn into the 40 mm diameter
ASA-stent, using bovine and porcine pericardium for the leaflets and a sealing skirt,
respectively. The smallest diameter was determined by crimping tests and a catheter was
adapted. The physiological function of the new prosthesis sample was tested in-vitro
inside a mock-loop, specifically designed for the simulation of the right heart. The valved
stent-construct was introduced into an anatomical silicone-model of the right heart to
analyze the adaptation to the heart structure and the prosthesis’ function in-vitro.
Results: The arched stent-construct of a vena cava superior-stent, five struts and a large
valved tricuspid annulus-stent could be crimped to fit the custom delivery catheter system.
The in-vitro tests showed good adaptation, enough flexibility of the struts, good seal and
a physiological pressure of 5/40 mmHg was applied.
Conclusions: The percutaneous tricuspid valve approach was proven to work with two
different designs, one already assessed in animal trials and one successful in in-vitro tests.
TCT-111
First In Man Experience with a Two-part, Exchangeable Leaflet Bioprosthetic
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Background: Revalving failed bioprostheses with transcatheter valves cannot be done
routinely because of diminished EOA and concerns for their long-term durability. A
two-part rapidly exchangeable tissue valve has been developed as an alternative. The
design of the valve was inspired by the off-patent features of the Edwards Perimount/
Magna series. It is a two-component valve where the permanent base can be implanted
without the leaflets, improving visibility and hence speed of implant. The removable
leaflet set can later be exchanged via transapical access, off-pump.
Methods: Animal studies have shown calcification resistance superior to the Perimount,
and bench studies show greater EOA than the Magna, and durability greater than 200
million cycles at a closing pressure of 200 mmHg. In its first clinical use, 23-mm size
valves were implanted into three men, two with bicuspid valves and one with senile aortic
valve stenosis. Two were placed with infra-annular pledgets and one with supra-annular
pledgets. The base was inserted first and then the leaflet set was attached with the aid of
clear plastic shields that protected the 2-mm high post.
Results: Placement of the base first allowed easier valve insertion, as tall commissural
posts, found in current pericardial valves were not present to obstruct suture tying.
Furthermore, the absence of leaflets allowed additional infra-valvular sutures to be placed
without difficulty.
Conclusions: This new valve shows promise for easier insertion and good durability. In
addition it may facilitate leaflet-set exchange, should it deteriorate later. Further study
appears to be justified for early and late results.
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Software; Improves Management Of Patients With ST-Segment Elevation
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Background: A pre-hospital electrocardiogram (ECG) improves the management of
patients with ST-segment elevation myocardial infarction (STEMI). Current telecommu-
nication systems do not permit real-time interaction with first responders in the field or
with care providers at referring hospitals. Our institution has developed a novel
telecommunications system based on a software application that is downloadable to
multiple platforms to permit real-time, two-way video and voice interaction over a
secured, HIPPA compliant network.
Methods: We hypothesized that the use of the CodeHeart application (CHap) for patients
with possible acute coronary syndrome will reduce door-to-balloon (DTB) times of
STEMI patients. Therefore, all STEMI system activations after implementation of the
CHap system, were prospectively entered into a database. Consecutive CHap activations
were compared to routine activations as controls, during the same time period (03/14/2011
to 12/31/2011). System quality measures were calculated and compared using Student’s
t test or the Mann-Whitney U test as appropriate.
Results: A total of 360 STEMI system activations occurred. 62 (17%) employed CHap
and 298 (83%) routine channels. DTB times were reduced by the use of CHap when
compared to controls (95.335’ vs. 154.6102.4’, p0.0009) as were first call-to-
balloon times (68.929.3’ vs. 91.740’, p0.004), which highlights our network’s
response efficiency for transferred patients. The percentage of catheterization laboratory
activations for a true STEMI was higher with the use of CHap, although this trend did not
reach statistical significance. [CHap 38/62 (61.3%) vs. routine 148/298 (49.7%), p0.12].
Conclusions: The implementation of a two-way telecommunications system that allows
for real-time interactions between interventional cardiologists and referring practitioners
MONDAY, OCTOBER 22, 8:00 AM–6:15 PM www.jacc.tctabstracts2012.com
B34 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/ORAL/Interventional Innovation
O
R
A
L
S
